Deans' stroke musings: Proteome Sciences plc : Stroke Biomarker License to Randox

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, April 5, 2012

Proteome Sciences plc : Stroke Biomarker License to Randox

And with a simple blood test we could eliminate the extensive MRI and neurologist infrastructure in order to deliver tPA faster. Its a good start but we still need a backup plan for when tPA doesn't work.
http://www.4-traders.com/PROTEOME-SCIENCES-PLC-4001272/news/PROTEOME-SCIENCES-PLC-Stroke-Biomarker-License-to-Randox-14259969/
Proteome Sciences plc ("Proteome Sciences") PRESS RELEASE Stroke Biomarker License to Randox 5th April 2012 - London. Proteome Sciences plc, a global leader in protein biomarkers has today granted a non-exclusive license to Randox Laboratories ("Randox") of Crumlin, UK for its portfolio of stroke biomarkers.

Proteome Sciences has established an extensive portfolio of patented plasma biomarkers of stroke and other brain damage-related disorders discovered in partnership with the Biomedical Proteomics Research Group at the University of Geneva. These markers are rapidly elevated in blood of patients undergoing both haemorrhagic and ischaemic strokes and offer the potential to identify those patients that would most benefit from thrombolytic treatment within the first 3 hours after onset of symptoms. The research with BPRG has shown that a panel of 5 blood proteins is able to accurately rule out 90% [9 out of 10] of patients that have not had a stroke but who may currently be misdiagnosed in primary care and allows 90% [9 out of 10] of genuine strokes to be confirmed within minutes of the onset of symptoms. Together, these results have the potential to transform the management of acute stroke and ensure more patients receive thrombolytic therapy. These provide a highly effective way to minimise long-term disability in ischaemic stroke, reduce the cost of care and considerably improve the quality of life for stroke patients and their families.
Under the terms of the Agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Financial terms provide Proteome Sciences with seven digit (US dollar) license and development milestones together with double digit royalties on sales.
The clinical discovery and validation of the stroke biomarkers was led by Prof Jean-Charles Sanchez, Director of the University of Geneva Biomedical Proteomics Research Group who commented "The discovery and validation of a panel of early stroke biomarkers in blood opens the way for rapid detection and selection of treatment that will have profound benefits for patients, their families and carers. We have recently studied the potential impact of using just one of these markers, GST-Pi, and found it could increase the number of treated stroke patients five-fold."
Dr. Ian Pike, Chief Operating Officer of Proteome Sciences said "We are pleased to be partnering our advanced stroke biomarkers with Randox who are rapidly developing a strong presence in the CNS area. Their track record of new product introductions has been impressive and we see their testing platforms as an ideal setting for rapid stroke diagnosis."
Dr. Peter FitzGerald, Managing Director at Randox commented "the addition of the Proteome Sciences stroke biomarkers will add significantly to the range of diagnostic products we offer in the cardiovascular disease field. Our ability to deliver these novel biomarkers to healthcare providers using our Biochip Array systems will enable stratification of patients for appropriate treatment and contribute to a reduction in healthcare costs. The stroke biomarkers will be offered to hospital laboratories through our global distribution network in 130 countries
Christopher Pearce, Chief Executive of Proteome Sciences said "The stroke biomarkers licensed to Randox have the ability to transform the way stroke is managed and ensure that considerably more patients receive treatment early. This will reduce the levels of disability, lower the cost of care and improve patient outcomes. We are delighted that the importance of our proprietary biomarkers is being properly recognised in diagnostics and drug development. Whilst licensing to companies like Randox remains a key component of our business, we also provide direct testing services through our
ISO 9001:2008 certified facility and rapidly increased the number of biomarkers where we had assay coverage to around 50 by the end of 2011 and this number will double in 2012 with revenue reflected through PS Biomarker Services™."